Department of Clinical Genetics, Erasmus University Medical Center Rotterdam, Erasmus MC, 3015 GD Rotterdam, The Netherlands.
Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, Sorbonne Université, Paris, France.
Brain. 2023 Apr 19;146(4):1496-1510. doi: 10.1093/brain/awac326.
The protein phosphatase 2A complex (PP2A), the major Ser/Thr phosphatase in the brain, is involved in a number of signalling pathways and functions, including the regulation of crucial proteins for neurodegeneration, such as alpha-synuclein, tau and LRRK2. Here, we report the identification of variants in the PTPA/PPP2R4 gene, encoding a major PP2A activator, in two families with early-onset parkinsonism and intellectual disability. We carried out clinical studies and genetic analyses, including genome-wide linkage analysis, whole-exome sequencing, and Sanger sequencing of candidate variants. We next performed functional studies on the disease-associated variants in cultured cells and knock-down of ptpa in Drosophila melanogaster. We first identified a homozygous PTPA variant, c.893T>G (p.Met298Arg), in patients from a South African family with early-onset parkinsonism and intellectual disability. Screening of a large series of additional families yielded a second homozygous variant, c.512C>A (p.Ala171Asp), in a Libyan family with a similar phenotype. Both variants co-segregate with disease in the respective families. The affected subjects display juvenile-onset parkinsonism and intellectual disability. The motor symptoms were responsive to treatment with levodopa and deep brain stimulation of the subthalamic nucleus. In overexpression studies, both the PTPA p.Ala171Asp and p.Met298Arg variants were associated with decreased PTPA RNA stability and decreased PTPA protein levels; the p.Ala171Asp variant additionally displayed decreased PTPA protein stability. Crucially, expression of both variants was associated with decreased PP2A complex levels and impaired PP2A phosphatase activation. PTPA orthologue knock-down in Drosophila neurons induced a significant impairment of locomotion in the climbing test. This defect was age-dependent and fully reversed by L-DOPA treatment. We conclude that bi-allelic missense PTPA variants associated with impaired activation of the PP2A phosphatase cause autosomal recessive early-onset parkinsonism with intellectual disability. Our findings might also provide new insights for understanding the role of the PP2A complex in the pathogenesis of more common forms of neurodegeneration.
蛋白磷酸酶 2A 复合物(PP2A)是大脑中主要的丝氨酸/苏氨酸磷酸酶,参与许多信号通路和功能,包括调节神经退行性变的关键蛋白,如α-突触核蛋白、tau 和 LRRK2。在这里,我们报告了在两个具有早发性帕金森病和智力障碍的家族中,编码主要 PP2A 激活剂的 PTPA/PPP2R4 基因变异的鉴定。我们进行了临床研究和遗传分析,包括全基因组连锁分析、外显子组测序和候选变异的 Sanger 测序。接下来,我们在培养细胞和敲低 Drosophila melanogaster 中的 ptpa 上进行了与疾病相关的变异的功能研究。我们首先在一个具有早发性帕金森病和智力障碍的南非家族的患者中鉴定出一个纯合 PTPA 变异,c.893T>G(p.Met298Arg)。对大量额外家族的筛选产生了另一个纯合变异,c.512C>A(p.Ala171Asp),在一个具有类似表型的利比亚家族中。这两种变异都与各自家族的疾病共分离。受影响的个体表现为青少年起病的帕金森病和智力障碍。运动症状对左旋多巴治疗和丘脑底核深部脑刺激有反应。在过表达研究中,PTPA p.Ala171Asp 和 p.Met298Arg 变异均与 PTPA RNA 稳定性降低和 PTPA 蛋白水平降低相关;p.Ala171Asp 变异还显示 PTPA 蛋白稳定性降低。至关重要的是,两种变异的表达都与 PP2A 复合物水平降低和 PP2A 磷酸酶激活受损相关。在果蝇神经元中敲低 PTPA 同源物导致在攀爬测试中运动能力显著受损。这种缺陷是年龄依赖性的,并且可以通过 L-DOPA 治疗完全逆转。我们得出结论,与 PP2A 磷酸酶激活受损相关的双等位基因错义 PTPA 变异导致常染色体隐性早发性帕金森病伴智力障碍。我们的发现还可能为理解 PP2A 复合物在更常见形式的神经退行性变发病机制中的作用提供新的见解。